Vancomycin susceptibility was checked in isolates from initial and final blood samples obtained from 22 patients with persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. The minimum inhibitory concentration of vancomycin was determined using Etest and found to have increased in 2 pairs of isolates, and results of screening in 4 mg vancomycin and a modified population analysis profile suggested heteroresistance in 3 isolates (13.6%). Heteroresistance is not a common cause of persistent or recurrent bacteremia.
Vancomycin susceptibility was checked in isolates from initial and final blood samples obtained from 22 patients with persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. The minimum inhibitory concentration of vancomycin was determined using Etest and found to have increased in 2 pairs of isolates, and results of screening in 4 mg vancomycin and a modified population analysis profile suggested heteroresistance in 3 isolates (13.6%). Heteroresistance is not a common cause of persistent or recurrent bacteremia.
The reports of vancomycin resistance or decreased vancomycin susceptibility among methicillin-resistant Staphylococcus aureus (MRSA) isolates continue to increase [1] [2] [3] [4] [5] . Additionally, heteroresistance among susceptible strains has been implicated in treatment failure [3, 6] . The prevalence of heteroresistance varies but appears to be rare in the United States [5, 7] . We elected to screen all isolates from patients with persistent and recurrent MRSA bacteremia to determine the prevalence of heteroresistance and whether it contributes to suboptimal response to therapy.
Methods. This study was conducted at a 600-bed teaching hospital in the Detroit area. Blood culture results were monitored from 1 January 2002 through 31 December 2002. All inpatients from whom samples were obtained that yielded MRSA in у1 culture were monitored. Isolates from initial and subsequent blood samples obtained from patients with persistent bacteremia (duration, у10 days) and from patients with recurrent bacteremia (duration, 130 days) were selected. Another isolate recovered from the mitral valve of 1 patient with persistent bacteremia was also included. The genomic DNA of initial blood isolates were analyzed with Sma endonuclease digestion and PFGE, as described elsewhere [8] .
Initial and subsequent blood isolates were inoculated onto a Mueller-Hinton (MH) agar plate and a brain-heart infusion (BHI) agar plate. After drying, a vancomycin Etest strip was applied, the plates were incubated at 35ЊC, and results were read at 24 h and 48 h. All tests were done in duplicate.
Isolates were also inoculated into BHI broth (Remel) and incubated overnight at 35ЊC. Turbidity was adjusted to 0.5 McFarland (∼ cfu/mL), and 10 mL of each suspension 7 5 ϫ 10 was spot inoculated onto BHI agar (Remel) containing 4 mg/ mL vancomycin (Sigma). Plates were incubated at 35ЊC and examined for growth at 24 h and 48 h. Each heteroresistant isolate was grown in BHI broth as stated above and adjusted to 0.5 McFarland. Serial 10-fold dilutions were prepared, and 100 mL of each suspension was inoculated onto 6 BHI agar plates supplemented with 0, 2, 4, 6, 8, and 10 mg/mL vancomycin. Plates were incubated at 35ЊC and examined for growth at 24 h and 48 h. The number of colony-forming units was counted by 2 independent observers. An S. aureus strain intermediately resistant to vancomycin-S. aureus subspecies aureus (ATCC #700699; Mu50)-and a susceptible strain (ATCC #29213) were included as positive and negative controls, respectively.
All isolates with growth in the presence of 4 or 6 mg of vancomycin were further screened with a modified population analysis profile method, as described by Wootton et al. [9] . In brief, these isolates were screened in vancomycin concentrations of 0.5, 1, 2, 2.5, and 4 mg. A heteroresistant S. aureus strain-S. aureus subspecies aureus (ATCC #700698; Mu3)-and ATCC #29213 were included as a positive and negative control, respectively. Colonies were counted after a 48-h incubation period at 37ЊC, a graph plotting the log 10 colony count (colony-forming units per milliliter) against the vancomycin concentration (0.5-4.0 mg/ mL) was constructed, and the area under the curve (AUC) was calculated. The ratio of the AUC for the test isolate divided by the AUC of the Mu3 control strain was determined. Heteroresistance among MRSA strains was defined as an AUC ratio у0.9. Results. Blood cultures were positive for MRSA in 118 cases. For 39 patients, bacteremia persisted for 10-39 days in 11 instances and recurred after 33-145 days in 11 instances (table 1) . These isolates were associated with 10 PFGE groups: 6 isolates and the Mu3 control strain clustered into a main group; 7 other isolates clustered into 1 of 3 groups, each of which differed from the main group by a single band; and the rest were distributed among 6 other groups. Most of these isolates (77.3%) were nosocomial and had a multidrug-resistant profile. A comparison of MICs of vancomycin determined using Vitek (bioMerieux) and Etest (in MH and BHI agar) analyses for isolates from initial and subsequent blood samples is shown in 
MICs of initial and subsequent isolates generally had identical results. Two pairs of isolates (9.1%)-1 each from patients 1 and 10, both of whom had persistent bacteremia-exhibited a 1-and 2.5-mg increase in MIC of vancomycin, respectively, as revealed by Etest in BMI agar. Additionally, a few colonies grew in the zone of the Etest strip with vancomycin concentrations of 5-32 mg. The subsequent isolate from a patient with recurrent bacteremia (patient 20) exhibited a vancomycin MIC that was lower than that of the initial isolate; both isolates exhibited variant colony morphology, suggesting that the relapse was caused by a new strain.
Isolates from patients 10, 17, and 19 and a valve isolate recovered from the mitral valve of patient 19 grew on screening agar. Population analysis of these isolates demonstrated a 2-3-log decrease in the colony count on agar plates supplemented with a 4-mg concentration of vancomycin, limited growth (10 2-3 cfu/mL) in a 6-mg concentration, and complete inhibition Modified population analysis of Staphylococcus aureus blood isolates from patient 10 (C-10), patient 17 (c-17), and patient 19 (C-19); a heteroresistant control strain (Mu3); and a methicillin-susceptible S. aureus (MRSA) control strain. Numbers in parentheses reflect the areaunder-the-curve (AUC) ratio (i.e., the ratio of the AUC for the test isolate divided by the AUC of the Mu3 control strain).
in an 8-mg concentration. ATCC #29213 exhibited slight growth in 2 mg vancomycin and was inhibited in concentrations у4 mg. Mu50 demonstrated a growth of -cfu/mL 6 6 1 ϫ 10 5 ϫ 10 in plates with р8 mg of vancomycin and cfu/mL in 2 2 ϫ 10 plates with 10 mg of vancomycin. A modified population analysis profile of the 3 blood isolates demonstrated growth similar to that of the Mu3 strain, with an AUC ratio of у0.9, implying heteroresistance ( figure 1) .
Discussion. Reports of detection of S. aureus isolates with decreased susceptibility to vancomycin are hampered because of unclear definitions [3, 9] . For standardization, the NCCLS set the MIC breakpoint for S. aureus susceptibility to vancomycin at р4 mg, intermediate susceptibility at 8-16 mg, and resistance at у32 mg [3] . Susceptible isolates that grow populations that exhibit higher MICs of vancomycin are defined as heteroresistant. These populations are more common for isolates with borderline vancomycin MICs (e.g., 4 mg). They develop in vivo during therapy or in vitro after passage in subinhibitory concentrations. The development appears to be dependant on genetic background of the S. aureus population [6, 10] . Current methods of detecting less-susceptible populations are inadequate [3, 7] . Moreover, this resistance appears to be unstable [2, 3] . These characteristics have contributed to uncertainty about the prevalence of heteroresistance and its actual significance.
On the basis of vancomycin screening, Etest MICs of vancomycin, and population analysis of screen-positive isolates, we detected 3 isolates that could be defined as heteroresistant, according to a modified population analysis profile method. The significance of such decreased susceptibility is unknown. Most of our patients did not have heteroresistant isolates, and those who did had other reasons for relapse or persistence. Similar uncertainties about the role of reduced susceptibility have been raised by Schwaber et al. [11] . These findings suggest that heteroresistance is probably uncommon, corroborating prior reports of heteroresistance infrequency in US isolates [7, 12] . In summary, heteroresistance among MRSA isolates from patients with persistent and recurrent bacteremia is uncommon, and resistant populations probably do not play a major role in persistence or relapse.
